Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/2007

01-09-2007 | Original Article

Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer

Authors: Lin Run Wang, Ming Zhu Huang, Guo Bing Zhang, Nong Xu, Xiu Hua Wu

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2007

Login to get access

Abstract

Purpose

To evaluate the efficacy and safety of gemcitabine in combination with carboplatin at standard rate or fixed dose rate infusion in patients with advanced non-small-cell lung cancer (NSCLC).

Patients and methods

In this prospective study, patients with chemonaive advanced NSCLC were randomized to receive gemcitabine at a standard rate (gemcitabine 1,200 mg/m2 over 30 min, the standard arm) or a fixed dose rate (gemcitabine 1,200 mg/m2 over 120 min, the FDR arm) on days 1 and 8 every 3 week cycle. In both treatment arms, carboplatin at AUC of 5 was administered over 4 h following gemcitabine on day 1 of each cycle.

Results

From November 2003 to June 2005, a total of 42 patients, in which 7 (17%) patients had stage IIIB disease and 35 (83%) had stage IV disease, were enrolled into this study. All patients were included in efficacy and toxicity assessment. No patient had a complete response. Seven (33%) patients in the standard arm and 10 (48%) in the FDR arm had a partial response. The median time to progression and median overall survival time in the standard arm was 5.4 months (95% CI, 3.8–7 months) and 11.5 months (95% CI, 8.2–14.8 months), respectively, while in the FDR arm was 6.5 (95% CI, 4.4–8.6 months) months, 12.0 months (95% CI, 11.3–12.7 months), respectively. The most frequently reported grade 3 or 4 hematological toxicities were thrombocytopenia (38% patients in the standard arm and 43% in the FDR arm) and neutropenia (24% in the standard arm and 33% in the FDR arm). Although hematological toxicity occurred in a little higher percent of patients in the FDR arm than in the standard arm, there were no discernible differences by statistical analysis in both treatment arms (P > 0.05). And significant nonhematologic toxicities were infrequent and tolerable in both arms. No significant difference existed also (P > 0.05).

Conclusion

In this phase II study, gemcitabine in combination with carboplatin either at standard rate or fixed dose rate infusion was clinically effective and well tolerated in patients with advanced NSCLC.
Literature
1.
Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics,2002. CA Cancer J Clin 55:74–108PubMedCrossRef
2.
Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311:899–909
3.
Kosmidis PA, Kalofonos C, Syrigos K et al (2005) Paclitaxel and gemcitabine vs. carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 23:7000
4.
Rudd RM, Gower NH, Spiro SG et al (2005) Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. J Clin Oncol 23:142–153PubMedCrossRef
5.
Sederholm C, Hillerdal G, Lamberg K et al (2005) Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: The Swedish Lung Cancer Study Group. J Clin Oncol 23:8380–8388PubMedCrossRef
6.
Anderson H, Lund B, Bach F et al (1994) Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 12:1821–1826PubMed
7.
Abratt RP, Bezwoda WR, Falkson G et al (1994) Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12:1535–1540PubMed
8.
Ma CX, Nair S, Thomas S et al (2005) Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 23:5929–5937PubMedCrossRef
9.
Giovannetti E, Mey V, Nannizzi S et al (2005) Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol 68:110–118PubMed
10.
Giovannetti E, Mey V, Danesi R et al (2004) Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 10:2936–2943PubMedCrossRef
11.
Ogawa M, Hori H, Ohta T et al (2005) Sensitivity to gemcitabine and its metabolizing enzymes in neuroblastoma. Clin Cancer Res 11:3485–3493PubMedCrossRef
12.
Gandhi V, Plunkett W, Du M et al (2002) Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol 20:665–673PubMedCrossRef
13.
Tempero M, Plunkett W, Haperen VR et al (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402–3408PubMedCrossRef
14.
Grunewald R, Abbruzzese JL, Tarassoff P et al (1991) Saturation of 2′, 2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27:258–262PubMedCrossRef
15.
Abbruzzese JL, Grunewald R, Weeks EA et al (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491–498PubMed
16.
Grunewald R, Kantarjian H, Du M et al (1992) Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 10:406–413PubMed
17.
Furuse J, Ishii H, Okusaka T et al (2005) Phase I study of fixed dose rate infusion of gemcitabine in patients with unresectable pancreatic cancer. J Clin Oncol 35:733–738
18.
Gelibter A, Di Cosimo S, Ruggeri EM et al (2004) Fixed dose-rate gemcitabine (GEM) infusion in advanced pancreatic (PDAC) and biliary tree (BTC) carcinoma: a phase II study. ASCO Meeting Abstracts 22:4182
19.
Ko AH, Dito E, Schillinger B et al (2006) Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol 24:379–385PubMedCrossRef
20.
Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756PubMed
21.
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRef
22.
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481CrossRef
23.
Maestu I, Gomez-Aldaravi L, Torregrosa MD et al (2003) Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer. Lung Cancer 42:345–54PubMedCrossRef
24.
Parente B, Barroso A, Conde S et al (2001) A prospective study of gemcitabine and carboplatin as first-line therapy in advanced non-small cell lung cancer: toxicity of a three- versus a four-week schedule. Semin Oncol 28(Suppl):10–4PubMedCrossRef
25.
Mazzanti P, Massacesi C, Rocchi MB et al (2003) Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 41:81–9PubMedCrossRef
26.
Zatloukal P, Petruzelka L, Zemanova M et al (2003) Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 41:321–31PubMedCrossRef
27.
Domine M, Casado V, Estevez LG et al (2001) Gemcitabine and carboplatin for patients with advanced non-small cell lung cancer. Semin Oncol 28(Suppl):4–9PubMed
28.
Bajetta E, Stani SC, Candis DD et al (2003) Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer. Ann Oncol 14:242–247PubMedCrossRef
29.
Soo RA, Lim HL, Wang LZ et al (2003) Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group Study. Cancer Chemother Pharmacol 52(2):153–158PubMedCrossRef
30.
Wang LR, Huang MZ, Xu N et al (2005) Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer. J Zhejiang Univ Sci B 6:446–450PubMedCrossRef
31.
Bhargava P, Marshall JL, Fried K et al (2001) Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer. Cancer Chemother Pharmacol 48:95–103PubMedCrossRef
32.
Kroep JR, Giaccone G, Voorn DA et al (1999) Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non–small-cell lung cancer. J Clin Oncol 17:2190–2197PubMed
33.
Soo RA, Wang LZ, Tham LS et al (2006) A muticentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer. Ann Oncol 17:1128–1133PubMedCrossRef
34.
Parker RS, Fisher JW, Florian JA et al (2005) Development of a pharmacokinetically-guided gemcitabine (dFdC) dosing schedule to reduce potentially excessive plasma dFdC concentrations. ASCO MeetingAbstracts 23:2025
Metadata
Title
Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer
Authors
Lin Run Wang
Ming Zhu Huang
Guo Bing Zhang
Nong Xu
Xiu Hua Wu
Publication date
01-09-2007
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2007
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-007-0504-x

Other articles of this Issue 4/2007

Cancer Chemotherapy and Pharmacology 4/2007 Go to the issue

Original Article

Preclinical antitumor activity of the oral platinum analog satraplatin

Original Article

A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy male volunteers

Original Article

Targeting c-Src kinase enhances tamoxifen’s inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins

Original Article

R-etodolac (SDX-101) and the related indole–pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells

Short Communication

Is rectal administration an alternative route for imatinib?

Original Article

Influence of ketoconazole on the fecal and urinary disposition of docetaxel
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits